Lantheus Holdings, Inc.

Lantheus Holdings, Inc. (NASDAQ: LNTH) is the leading radiopharmaceutical-focused company committed to enabling clinicians to find, fight, and follow disease to deliver better patient outcomes. The company operates through three primary product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue.

The Radiopharmaceutical Oncology segment centers on PYLARIFY, an F-18-labeled PET imaging agent targeting prostate-specific membrane antigen approved by the FDA in 2021. PYLARIFY is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer and is manufactured through a diverse network of positron emission tomography manufacturing facilities across the United States, distributed to customers in 48 states plus the District of Columbia and Puerto Rico.

The Precision Diagnostics segment includes DEFINITY, an ultrasound enhancing agent used in echocardiography procedures that holds over 80 percent market share in the U.S. ultrasound enhancing agent segment, and Neuraceq, an F-18-labeled PET imaging agent for Alzheimer's disease diagnostics that the company acquired through its July 2025 acquisition of Life Molecular Imaging Limited. The Strategic Partnerships and Other Revenue segment encompasses biomarker solutions, digital imaging applications including aBSI and aPROMISE, contract development and manufacturing organization services through Evergreen Theragnostics, and royalties from licensed products including flurpiridaz and RELISTOR.

Lantheus maintains a global footprint with headquarters in Massachusetts and offices in New Jersey, Canada, Germany, Switzerland, Sweden, and the United Kingdom. The company serves cardiologists, neurologists, oncologists, radiologists, and other healthcare professionals through hospitals, independent imaging centers, and government facilities throughout the United States and internationally through direct distribution and third-party partnerships.

In 2025, the company executed significant strategic transactions including the acquisition of Life Molecular Imaging Limited and Evergreen Theragnostics, as well as the divestiture of its SPECT business to SHINE Technologies. These transactions reflect the company's strategic focus on growing its commercial portfolio of innovative PET radiodiagnostics and microbubbles while maintaining a robust pipeline of clinical-stage candidates in oncology and neurology.